The approach to pseudomonas aeruginosa in cystic fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 5, 2009, Pages 587-595

  Bendiak, Glenda N ^a,b   Ratjen, Felix ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antibiotic therapy; Cystic fibrosis; Eradication; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZLOCILLIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; NEOMYCIN; OFLOXACIN; PLACEBO; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; BREATHING EXERCISE; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA INFECTION; CLINICAL TRIAL; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; HYGIENE; INFECTION PREVENTION; LUNG FIBROSIS; LUNG FUNCTION; MAINTENANCE THERAPY; NEPHROTOXICITY; NUTRITIONAL SUPPORT; OBSERVATIONAL STUDY; OTOTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; REVIEW; THROAT CULTURE; TREATMENT DURATION; VACCINATION;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; HYGIENE; LUNG; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 70350449606     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1238917     Document Type: Review

References (95)

1. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003 361 681-689
2. Li Z, Kosorok M R., Farrell P M. et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005 293 581-588
3. Cystic Fibrosis Foundation. Patient Registry 2007 Annual Data Report. Bethesda, MD Cystic Fibrosis Foundation 2008
4. Smith J J., Travis S M., Greenberg E P., Welsh M J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996 85 229-236
5. Pier G B., Grout M, Zaidi T S. et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996 271 64-67
6. Noone P G., Leigh M W., Sannuti A et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004 169 459-467
7. Gibson R L., Burns J L., Ramsey B W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003 168 918-951
8. Burns J L., Gibson R L., McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001 183 444-452
9. Fegan M, Francis P, Hayward A C., Davis G H., Fuerst J A. Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis. J Clin Microbiol 1990 28 1143-1146
10. Levy H, Kalish L A., Cannon C L. et al. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol 2008 43 463-471
11. Konstan M W., Morgan W J., Butler S M. et al, Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007 151 134-139, 139, e1
12. Courtney J M., Bradley J, Mccaughan J et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007 42 525-532
13. Henry R L., Mellis C M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992 12 158-161
14. Nixon G M., Armstrong D S., Carzino R et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001 138 699-704
15. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002 34 91-100
16. Schelstraete P, Van Daele S, De Boeck K et al. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients. Eur Respir J 2008 31 822-829
17. Green S K., Schroth M N., Cho J J., Kominos S K., Vitanza-jack V B. Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa. Appl Microbiol 1974 28 987-991
18. Regnath T, Kreutzberger M, Illing S, Oehme R, Liesenfeld O. Prevalence of Pseudomonas aeruginosa in households of patients with cystic fibrosis. Int J Hyg Environ Health 2004 207 585-588
19. Barben J, Hafen G, Schmid J, Swiss Paediatric Respiratory Research Group. Pseudomonas aeruginosa in public swimming pools and bathroom water of patients with cystic fibrosis. J Cyst Fibros 2005 4 227-231
20. Whitby J L., Rampling A. Pseudomonas aeruginosa contamination in domestic and hospital environments. Lancet 1972 1 15-17
21. Döring G, Jansen S, Noll H et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996 21 90-100
22. Zimakoff J, Høiby N, Rosendal K, Guilbert J P. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983 4 31-40
23. Festini F, Taccetti G, Mannini C et al. Patient risk of contact with respiratory pathogens from inanimate surfaces in a cystic fibrosis outpatient clinic: a prospective study over a four-year period. Pediatr Pulmonol 2007 42 779-784
24. Speert D P., Campbell M E. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987 9 11-21
25. Grothues D, Koopmann U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988 26 1973-1977
26. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000 29 177-181 (Pubitemid 30141793)
27. Brimicombe R W., Dijkshoorn L, van der Reijden T J. et al. Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in the Netherlands. J Cyst Fibros 2008 7 30-36
28. Jones A M., Govan J RW, Doherty C J. et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001 358 557-558
29. Griffiths A L., Jamsen K, Carlin J B. et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 2005 171 1020-1025
30. Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003 31 (3, Suppl) S1-S62
31. Lang A B., Rüdeberg A, Schöni M H., Que J U., Fürer E, Schaad U B. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004 23 504-510
32. Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007 104 11020-11025
33. Johansen H K., Gøtsche P C. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008 (4) CD001399
34. Steinkamp G, Tümmler B, Malottke R, von der Hardt H. Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 1989 64 1022-1028
35. Littlewood J M., Miller M G., Ghoneim A T., Ramsden C H. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985 1 865
36. Valerius N H., Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991 338 725-726
37. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997 23 330-335
38. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005 26 458-461
39. Lee T WR, Brownlee K G., Denton M, Littlewood J M., Conway S P. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004 37 104-110
40. Hansen C R., Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008 7 523-530
41. Wiesemann H G., Steinkamp G, Ratjen F et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998 25 88-92
42. Ratjen F, Döring G, Nikolaizik W H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001 358 983-984
43. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007 42 249-255
44. Rosenfeld M, Emerson J, Accurso F et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999 28 321-328
45. Gibson R L., Emerson J, McNamara S et al, Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 167 841-849
46. Gibson R L., Emerson J, Mayer-Hamblett N et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007 42 610-623
47. Ratjen F, Munck A, Kho P. Short and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: The ELITE study [abstract]. Pediatr Pulmonol 2008 S31 319-320
48. United States National Institutes of Health. Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis (EPIC). http://clinicaltrials.gov/ct2/show/NCT00097773?term=epic&rank=25 Accessed March 30, 2009
49. Pritt B, OBrien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol 2007 128 32-34
50. May T B., Shinabarger D, Maharaj R et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991 4 191-206
51. Pier G B., Coleman F, Grout M, Franklin M, Ohman D E. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun 2001 69 1885-1901
52. Murray T S., Egan M, Kazmierczak B I. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007 19 83-88
53. Singh P K., Schaefer A L., Parsek M R., Moninger T O., Welsh M J., Greenberg E P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000 407 762-764
54. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006 12 428-432
55. Levy J. Antibiotic activity in sputum. J Pediatr 1986 108 (5 Pt 2) 841-846
56. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000 288 1251-1254
57. Steinkamp G, Tümmler B, Gappa M et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989 6 91-98
58. MacLusky I B., Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989 7 42-48
59. Ramsey B W., Pepe M S., Quan J M. et al, Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999 340 23-30
60. Murphy T D., Anbar R D., Lester L A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004 38 314-320
61. Flume P A., O'sullivan B P., Robinson K A. et al, Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007 176 957-969
62. Jensen T, Pedersen S S., Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987 19 831-838 (Pubitemid 17092071)
63. Hodson M E., Gallagher C G., Govan J RW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002 20 658-664
64. McCoy K S., Quittner A L., Oermann C M., Gibson R L., Retsch-Bogart G Z., Montgomery A B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008 178 921-928
65. United States National Institutes of Health. International safety and efficacy study of aztreonam lysinate for inhalation (AI) in cystic fibrosis patients. http://www.clinicaltrials.gov/ct2/show/NCT00112359?cond= %22Cystic+Fibrosis%22&rank=12 Accessed March 30, 2009
66. United States National Institutes of Health. Aztreonam for inhalation solution versus tobramycin nebuliser solution in patients with cystic fibrosis and P. aeruginosa, followed by an open-label, single arm extension. http://www.clinicaltrials.gov/ct2/show/NCT00757237?cond= %22Cystic+Fibrosis%22&rank=110 Accessed March 30, 2009
67. United States National Institutes of Health. Multidose safety and tolerability study of (Arikace) for inhalation in cystic fibrosis patients. http://www.clinicaltrials.gov/ct2/show/NCT00558844?cond= %22Cystic+Fibrosis%22&rank=8 Accessed March 30, 2009
68. United States National Institutes of Health. Multidose safety and tolerability study of dose escalation of liposomal amikacin for inhalation (ARIKACE). http://www.clinicaltrials.gov/ct2/show/NCT00777296?cond= %22Cystic+Fibrosis%22&rank=194 Accessed March 30, 2009
69. United States National Institutes of Health. Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis. http://www.clinicaltrials.gov/ct2/show/NCT00645788?cond= %22Cystic+Fibrosis%22&rank=71 Accessed March 30, 2009
70. United States National Institutes of Health. Safety, pharmacokinetic and pharmacodynamic study of MP-376 in patients with cystic fibrosis. http://www.clinicaltrials.gov/ct2/show/NCT00503490?cond= %22Cystic+Fibrosis%22&rank=223 Accessed March 30, 2009
71. United States National Institutes of Health. Safety, tolerability and efficacy of MP-376 given for 28 days to cystic fibrosis (CF) patients. http://www.clinicaltrials.gov/ct2/show/NCT00677365?cond= %22Cystic+Fibrosis%22&rank=228 Accessed March 30, 2009
72. United States National Institutes of Health. Study evaluating fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. http://www.clinicaltrials.gov/ct2/show/ NCT00794586?cond=%22Cystic+Fibrosis%22&rank=95 Accessed March 30, 2009
73. United States National Institutes of Health. Safety of tobramycin inhalation powder (TIP) vs tobramycin solution for inhalation in patients with cystic fibrosis. http://www.clinicaltrials.gov/ct2/show/NCT00388505?cond= %22Cystic+Fibrosis%22&rank=147 Accessed March 30, 2009
74. Labro M T. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998 41 (Suppl B) 37-46
75. Tateda K, Ishii Y, Matsumoto T et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996 40 2271-2275
76. Saiman L, Marshall B C., Mayer-Hamblett N et al, Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003 290 1749-1756
77. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002 57 212-216
78. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J-P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006 61 895-902
79. Elborn J S., Prescott R J., Stack B HR et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000 55 355-358
80. Bradley J, McAlister O, Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J 2001 17 712-715
81. Ramsey B W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996 335 179-188
82. Balfour-Lynn I M., Elborn J S. Respiratory disease: infection In: Hodson M, Geddes D, Bush A Cystic Fibrosis. 3rd ed. London Hodder Arnold 2007 138
83. Fuchs H J., Borowitz D S., Christiansen D H. et al, The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994 331 637-642
84. Michel B C. Antibacterial therapy in cystic fibrosis: a review of the literature published between 1980 and February 1987. Chest 1988 94 (2, Suppl) 129S-140S
85. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1987 111 (6 Pt 1) 907-913
86. Regelmann W E., Elliott G R., Warwick W J., Clawson C C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990 141 (4 Pt 1) 914-921
87. Smith A L., Fiel S B., Mayer-Hamblett N, Ramsey B, Burns J L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003 123 1495-1502
88. Foweraker J E., Laughton C R., Brown D FJ, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005 55 921-927
89. Keays T, Ferris W, Vandemheen K L. et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009 8 122-127
90. United States National Institutes of Health. Use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy. http://www.clinicaltrials.gov/ct2/show/NCT00786513?cond= %22Cystic+Fibrosis%22&rank=214 Accessed March 30, 2009
91. Smyth A, Tan K HV, Hyman-Taylor P et al, TOPIC Study Group. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosisthe TOPIC study: a randomised controlled trial. Lancet 2005 365 573-578
92. Lam W, Tjon J, Seto W et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother 2007 59 1135-1140
93. Elborn J S., Prescott R J., Stack B HR et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000 55 (5) 355-358
94. Hodson M E., Roberts C M., Butland R JA, Smith M J., Batten J C. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987 1 235-237
95. Jensen T, Pedersen S S., Høiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol 1987 6 618-622